Page 2


  • A building showing a logo of Teva Pharmaceutical
    Image attribution tooltip
    Courtesy of Teva Pharmaceutical

    Teva taps Sandoz veteran to take over CEO post from Schultz

    Richard Francis will take over for the retiring Kåre Schultz on Jan. 1. He’ll face major challenges at Teva, including opioid settlements, biosimilar launches and reducing the company’s debt.

  • A wall showing a Merck & Co. logo in Kenilworth, New Jersey
    Image attribution tooltip
    Courtesy of Merck & Co.

    Merck to buy blood cancer biotech Imago for $1.35B

    The deal is Merck’s second notable acquisition in the past year and a half, part of a strategy to diversify its pipeline beyond the top-selling Keytruda.

  • Scientists working in an R&D laboratory
    Image attribution tooltip
    Courtesy of Merck KGaA

    Merck KGaA outlines plan to rev up drug R&D

    The German company aims to, on average, launch a new medicine or major treatment indication every 18 months in a bid to boost its pharma business.

  • A picture of the street sign stating "Wall Street." American flags drape over a nearby building
    Image attribution tooltip
    Kena Betancur via Getty Images
    Deep Dive

    Health tech companies weigh funding options amid weak IPO market

    Healthcare technology companies are delaying initial share sales and searching for new sources of cash. Experts don’t expect a quick recovery.

  • Portrait of Gideon Bollag, Opna Bio's CEO.
    Image attribution tooltip
    Permission granted by Opna Bio

    Cancer drugmaker Plexxikon gets new life as Opna Bio

    Eight months after Daiichi Sankyo shuttered the San Francisco Bay Area subsidiary, Plexxikon’s former CEO is resuscitating its drug research under a new name.

  • An illustration of a herpes simplex virus
    Image attribution tooltip
    Dr_Microbe via Getty Images

    Replay reveals second gene therapy spinout, debuting new biotech Telaria

    Telaria is the second spinout in Replay’s “hub-and-spoke” model, and will focus on developing a gene therapy for recessive dystrophic epidermolysis bullosa.

  • A sign for the Food And Drug Administration is seen outside of the headquarters on July 20, 2020 in White Oak, Maryland.
    Image attribution tooltip
    Sarah Silbiger via Getty Images

    First-of-its-kind Type 1 diabetes drug wins FDA approval

    Provention Bio’s teplizumab is meant to prevent the onset of Type 1 diabetes. To be sold as Tzield, the drug will cost $193,900 for a typical full regimen. 

    FDA
  • FDA approves Rezvoglar as second ‘interchangeable’ insulin biosimilar

    Eli Lilly’s long-acting copycat drug, first approved in late 2021, now has a designation that will allow pharmacists to swap it for Sanofi’s Lantus.

    FDA
  • A 3D visualization of Laronde's endless RNA, or eRNA
    Image attribution tooltip
    Permission granted by Laronde

    Former Rubius CEO to lead buzzy Flagship startup

    Pablo Cagnoni was appointed CEO at the RNA drug startup Laronde days after departing Rubius, a once high-flying biotech that’s now laid off nearly all its employees and is seeking a sale. 

  • A photo of an Editas Medicine scientist in the lab.
    Image attribution tooltip
    Permission granted by Editas Medicine
    Gene editing

    Editas to seek partner for CRISPR medicine after lackluster study results

    While the biotech will not develop the gene editing therapy further on its own, CEO Gilmore O’Neill claimed the data are still a meaningful demonstration of what CRISPR can accomplish. 

  • A photo of a sign showing the Food and Drug Administration logo
    Image attribution tooltip
    Sarah Silbiger via Getty Images

    FDA panel votes in favor of Ardelyx’s once-rejected kidney disease drug

    The recommendation represents a surprising turnaround for Ardelyx’s drug, which the FDA put before an advisory committee only after the biotech appealed its rejection last year.

    FDA
  • A photo of Regeneron's Tarrytown, NY headquarters.
    Image attribution tooltip
    Regeneron

    Regeneron teams up with CytomX to develop dual-targeting cancer drugs

    Regeneron will pay CytomX $30 million to try to create bispecific antibody drugs that are safer and have a wider reach than existing treatments.  

  • Image attribution tooltip
    Spencer Platt via Getty Images

    Pfizer, BioNTech start study testing next COVID-19 vaccine

    The new candidate is meant to provide broader immunity over a longer period of time and is part of the companies’ strategy to stay ahead of a shifting coronavirus threat.

  • A financial graph on an abstract background
    Image attribution tooltip
    monsitj via Getty Images

    Biotechs reveal layoffs, research revamps in third quarter earnings

    Tricida, Harpoon, Freeline and three other small drug developers last week announced plans to cut staff or to reprioritize their drug development.

  • Xavier Becerra sits on a couch onstage at HLTH.
    Image attribution tooltip
    Rebecca Pifer/BioPharma Dive

    Divided Congress after midterms will allow HHS to execute on policy priorities, Becerra says

    The agency is focused on implementing drug price negotiation in Medicare and surprise billing regulations, according to the secretary.

  • An illustration showing swollen neurons with lamellar inclusions due to accumulation of gangliosides in lysosomes.
    Image attribution tooltip
    Dr_Microbe, iStock via Getty Images

    Freeline cuts back as it continues search for gene therapy partner

    The U.K. biotech will sell its German unit and lay off staff to save cash as it focuses on therapies for Gaucher and Fabry diseases.

  • Q&A // Emerging biotech

    Eli Lilly’s Julie Gilmore on finding up-and-coming companies and backing small biotechs

    Only a small fraction of the companies Lilly evaluates get into its incubator, according to Gilmore. Here’s how the big pharma selects them.

  • Portrait of John Mulligan, chief executive officer of Bonum.
    Image attribution tooltip
    Permission granted by Bonum Therapeutics

    After $250M Roche buyout, a startup plans a second strike with fresh funding

    Backed by the same investors and team as an immunotherapy biotech Roche bought in September, Bonum Therapeutics plans to develop “conditionally” active cancer medicines.

  • Image attribution tooltip
    Jacob Bell

    For ImmunoGen, persistence pays off as FDA clears ovarian cancer drug

    The approval makes Elahere the first wholly owned medicine the biotech has brought to market in its lengthy history.

  • Street signs for the intersection of Wall St. and Broad St., with the stripes of an American flag in the background.
    Image attribution tooltip
    Michael Santiago/Getty Images via Getty Images

    Acrivon cuts IPO price to raise $99M for plan to revive old Lilly cancer drug

    Acrivon is the 20th biotech company to go public this year, roughly a fifth of last year’s total at this time, and had to sell more shares at a lower price to complete the deal. 

  • Portrait of Joanne Kotz and Joel Barrish, two of Jnana Therapeutics' co-founders.
    Image attribution tooltip
    Permission granted by Jnana Therapeutics

    Jnana deepens ties with Roche and grabs a new round of funding

    The startup, developing drugs that target an untapped class of proteins called solute carriers, has now formed two lucrative alliances with the Swiss drugmaker since 2020.

  • Beta-Amyloid Plaques and Tau in the Brain
    Image attribution tooltip
    National Institute on Aging. (2017). "Beta-Amyloid Plaques and Tau in the Brain" [Image]. Retrieved from Flickr.

    Trial failures end latest hope for Roche’s Alzheimer’s drug

    Eight years after gantenerumab failed a Phase 3 study, the drug came up short in late-stage testing again, proving unable to meaningfully slow cognitive decline in two closely watched trials. 

  • A photo of Ionis CEO Brett Monia and Metagenomi CEO Brian Thomas.
    Image attribution tooltip
    Permission granted by Ionis Pharmaceuticals and Metagenomi
    Gene editing

    Ionis teams with Metagenomi and dives into gene editing

    The RNA drug developer is paying the richly funded startup $80 million in a wide-ranging alliance that marks its first foray into DNA editing medicines.

  • An illustration of dollar signs and small pills coming together to make one larger pill, representing a biopharma deal.
    Image attribution tooltip
    Brian Tucker / BioPharma Dive

    Narcan developer to be acquired by Indivior

    The deal, which could carry a total value of roughly $145 million, is in large part focused on a nasal formulation of the opioid overdose drug nalmefene.

  • Colorized scanning electron micrograph of a VERO E6 cell heavily infected with SARS-COV-2 virus particles, isolated from a patient sample.
    Image attribution tooltip
    National Institute of Allergy and Infectious Diseases. (2020). "Novel Coronavirus SARS-CoV-2" [Micrograph]. Retrieved from Flickr.

    Moderna data supports use of omicron booster over original vaccine

    New results show the two-pronged booster the FDA cleared in August sparks a stronger immune response against omicron and its subvariants than Moderna’s original shot.